Curis Files Prospectus Related To The Resale Of Up To 33,333,360 Common Shares
-13F Filing
Last updated: 2026-11-14 10:50:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Curis Inc. (CRIS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.45, with a market capitalization of $1.39M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.33 to $28.40. This page covers its latest market performance, valuation, price trends and company information.
$1.39M | |
$0.50 | |
$0.52 | |
$0.42 | |
$0.57 | |
687.75K | |
4.01M | |
-- | |
$28.40 | |
$0.33 | |
-- | |
-- |
Curis Inc. (CRIS) last closed at $0.45 as of 2026-11-14 01:00:00, down 22.35% ($0.13) from the previous close of $0.57.
During the latest regular trading session, CRIS traded between $0.42 and $0.52, with a volume of 687.75K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Curis Inc. (CRIS) moved from $0.85 to $0.45, representing a decline of 47.53% ($0.40).
The stock traded between $0.42 and $1.09 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.76 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.4%
CRIS is currently trading at $0.45, placing it 0.4% of the way from its 52-week low of $0.33 to its 52-week high of $28.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 24 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Curis Inc. and CRIS stock.
-13F Filing
HC Wainwright & Co. analyst Sara Nik maintains Curis (NASDAQ:CRIS) with a Buy and lowers the price target from $43 to $6.
Curis reported Q3 2026 results highlighting progress on its lead oncology program emavusertib. The company announced an 86% response rate in BTK-naive patients with PCNSL (compared to 39-67% for BTK inhibitor monotherapy alone) and a 26% response rate in salvage-line patients. A CLL study was initiated with 12 patients enrolled across 11 sites, with initial data expected by year-end. The company reported a net loss of $8.1 million for Q3 2026 and $5 million in cash, with runway into 2027. Full enrollment in the PCNSL registrational study is expected by end of 2027, with NDA filing anticipated in 2028.
Eligible investors can buy real shares of Curis Inc. (CRIS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CRIS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CRIS shares and USD.
CRIS Shares to USD
1.00 CRIS shares = 0.446 USD
Calculations are estimates based on the latest available price and are for reference only.